[go: up one dir, main page]

WO2003049694A3 - Methods of therapy for non-hodgkin's lymphoma - Google Patents

Methods of therapy for non-hodgkin's lymphoma Download PDF

Info

Publication number
WO2003049694A3
WO2003049694A3 PCT/US2002/039253 US0239253W WO03049694A3 WO 2003049694 A3 WO2003049694 A3 WO 2003049694A3 US 0239253 W US0239253 W US 0239253W WO 03049694 A3 WO03049694 A3 WO 03049694A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphoma
methods
antibody
therapeutic
hodgkin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/039253
Other languages
French (fr)
Other versions
WO2003049694A2 (en
Inventor
Maurice J Wolin
Sandra Milan
Deborah Hurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/293,664 external-priority patent/US20030185796A1/en
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to CA002469045A priority Critical patent/CA2469045A1/en
Priority to JP2003550745A priority patent/JP2005538034A/en
Priority to EP02797231A priority patent/EP1463524A4/en
Priority to AU2002362098A priority patent/AU2002362098A1/en
Publication of WO2003049694A2 publication Critical patent/WO2003049694A2/en
Publication of WO2003049694A3 publication Critical patent/WO2003049694A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for treating a human with lymphoma using a combination of interleukin-2 and at least one anti-CD20 antibody are provided. These therapeutic agents are administered as two separate pharmaceutical compositions, one containing IL-2, the other containing at least one anti-CD20 antibody, according to a dosing regimen. Administering of these two therapeutic agents together potentiates the effectiveness of either agent alone, resulting in a positive therapeutic response that is improved with respect to that observed with either agent alone. The therapeutic effects of these agents can be achieved using lower dosages of IL-2, thereby lessening the toxicity of prolonged IL-2 administration and the potential for tumor escape.
PCT/US2002/039253 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma Ceased WO2003049694A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002469045A CA2469045A1 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma
JP2003550745A JP2005538034A (en) 2001-12-07 2002-12-06 Treatment of non-Hodgkin lymphoma
EP02797231A EP1463524A4 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin s lymphoma
AU2002362098A AU2002362098A1 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1796801A 2001-12-07 2001-12-07
US10/017,968 2001-12-07
US10/293,664 2002-11-12
US10/293,664 US20030185796A1 (en) 2000-03-24 2002-11-12 Methods of therapy for non-hodgkin's lymphoma

Publications (2)

Publication Number Publication Date
WO2003049694A2 WO2003049694A2 (en) 2003-06-19
WO2003049694A3 true WO2003049694A3 (en) 2003-11-06

Family

ID=26690566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039253 Ceased WO2003049694A2 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma

Country Status (5)

Country Link
EP (1) EP1463524A4 (en)
JP (1) JP2005538034A (en)
AU (1) AU2002362098A1 (en)
CA (1) CA2469045A1 (en)
WO (1) WO2003049694A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969980A (en) * 2008-01-17 2011-02-09 菲洛根股份公司 Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart
US9683047B2 (en) 2008-09-16 2017-06-20 Genentech, Inc. Methods for treating progressive multiple sclerosis

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
PL1631313T3 (en) 2003-06-05 2015-08-31 Genentech Inc Combination therapy for b cell disorders
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
WO2005062929A2 (en) * 2003-12-22 2005-07-14 Chiron Coporation Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
EP2431050A1 (en) 2004-05-20 2012-03-21 ZymoGenetics, L.L.C. Methods of treating cancer using IL-21 and monoclonal antibody therapy
AR049200A1 (en) 2004-06-04 2006-07-05 Genentech Inc METHOD TO TREAT MULTIPLE SCLEROSIS WITH A COMPOSITION CONTAINING A CD20 ANTIBODY
WO2006089064A1 (en) * 2005-02-15 2006-08-24 Novartis Vaccines And Diagnostics Inc. Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
JP2008545958A (en) 2005-05-20 2008-12-18 ジェネンテック・インコーポレーテッド Pretreatment of biological samples from subjects with autoimmune disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (en) 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
KR102262298B1 (en) 2007-07-09 2021-06-07 제넨테크, 인크. Prevention of disulfide bond reduction during recombinant production of polypeptides
AU2008312406B2 (en) 2007-10-16 2014-03-06 Ares Trading S.A. Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102498206A (en) 2009-08-11 2012-06-13 弗·哈夫曼-拉罗切有限公司 Protein production in glutamine-free cell culture media
CN102933231B (en) 2010-02-10 2015-07-29 伊缪诺金公司 CD20 antibody and its use
HUE057952T2 (en) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
CN114057884A (en) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 Bispecific anti-human CD20/human transferrin receptor antibody and methods of use
CN115521913B (en) * 2022-02-22 2023-07-25 北京景达生物科技有限公司 NK cells and CD20, CD38 and Her2 antibodies combined application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009427A1 (en) * 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009427A1 (en) * 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1463524A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969980A (en) * 2008-01-17 2011-02-09 菲洛根股份公司 Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart
US9683047B2 (en) 2008-09-16 2017-06-20 Genentech, Inc. Methods for treating progressive multiple sclerosis
US9994642B2 (en) 2008-09-16 2018-06-12 Genentech, Inc. Methods for treating progressive multiple sclerosis

Also Published As

Publication number Publication date
JP2005538034A (en) 2005-12-15
EP1463524A2 (en) 2004-10-06
CA2469045A1 (en) 2003-06-19
AU2002362098A1 (en) 2003-06-23
WO2003049694A2 (en) 2003-06-19
EP1463524A4 (en) 2005-02-09
AU2002362098A8 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
NZ217483A (en) Composition for delivery of hydrophobic drugs
NO332893B1 (en) Use of antibody for the preparation of drug for use in CVP chemotherapy
CR6458A (en) VALDECOXIB COMPOSITIONS
GB2316004A (en) Novel formulations for transdermal delivery of pergolide
ATE321529T1 (en) DOSAGE FORM FOR A DELAYED AND INCREASING RELEASE OF ACTIVE INGREDIENTS
ATE102838T1 (en) COMPOSITIONS FOR THE TREATMENT OF NEOPLASIA CONTAINING AN NEOPLASM INHIBITING AGENT AND SIDE EFFECT REDUCING PROTECTIVE AGENT.
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
DE60327843D1 (en) MEDICAMENT FORMULATIONS WITH DELAYED RELEASE WITH A CARRIER PEPTIDE
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
DE69434121D1 (en) PHARMACEUTICAL COMPOSITION FOR IMMUNITIMULATING THERAPY
DE60036915D1 (en) USE OF HYALURONAN FOR THE PREPARATION OF A MEDICAMENT FOR INCREASING THE EFFICACY OF CYTOTOXIC DRUGS
RU95101385A (en) Products containing g-csf and tnf-binding protein
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
AR015744A1 (en) USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
WO2001074365A3 (en) An efficacious dosage regimen of galantamine that reduces side effects
GB0018322D0 (en) Pharmaceutical compositions
KR930003913A (en) Methods and pharmaceutical compositions for enhancing the antitussive effect of dextromethorphan
EP1374873A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUPPRESSION OF SIDE EFFECTS CAUSED BY RADIATION THERAPY AND CHEMOTHERAPY
EP0272393A3 (en) Pharmaceutical combination
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
MXPA04002099A (en) Medicinal compositions for diabetic neuropathy.
KR870010871A (en) Intraoperative Treatment of Basal Cell Carcinoma by Recombinant Human Alpha Interferon
WO2003061571A3 (en) Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003550745

Country of ref document: JP

Ref document number: 2469045

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002797231

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002797231

Country of ref document: EP